Agile Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Agile Therapeutics

30/10/2021 03:03

* Agile Therapeutics Inc  AGRX.OQ   AGRX.O  is expected to show
a rise in quarterly revenue when it reports results on November
2. 
* The Princeton, New Jersey-based company is expected to report
revenue of $1.462 million, according to the mean estimate from 4
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for Agile Therapeutics Inc
is for a loss of 19 cents per share. For the same quarter last
year, the company reported a loss of 18 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Agile
Therapeutics Inc is $4​, about 80.2% above​ its last closing
price of $0.79. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.22       -0.22      -0.20     Beat    7.4
 Mar. 31 2021  -0.21       -0.21      -0.20     Beat    6.5
 Dec. 31 2020  -0.23       -0.22      -0.20     Beat    10.7​
 Sep. 30 2020  -0.18       -0.18      -0.18     Met     -1.1
 Jun.          -0.14​      -0.14      -0.12     Beat    14.3​
 30​ 2020​                                              
 Mar. 31 2020  -0.09       -0.09      -0.10     Missed  -13.6​
 Dec. 31 2019  -0.07       -0.07      -0.10     Missed  -33.3
 Sep. 30 2019  -0.08       -0.08      -0.08     Met     2
 This summary was machine generated October 30 at 02:03 GMT.  All
figures in US dollars unless otherwise stated